Sugi Predict

Sugi Predict / Compounds / SCHEMBL188384

SCHEMBL188384

SCHEMBL188384

N[C@@H](CCCC(F)(F)F)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 2/20 0.56
▸ ARG2 P78540 4/20 0.50
▸ ARG1 P05089 3/20 0.50
▸ NOS2 P35228 6/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ GLA P06280 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ APEX1 P27695 1/20 0.48
▸ GRM8 O00222 1/20 0.48
▸ GRM6 O15303 1/20 0.48
▸ GRIN2D O15399 1/20 0.48
▸ GRIN3B O60391 1/20 0.48
▸ GRIK1 P39086 1/20 0.48
▸ GRM5 P41594 1/20 0.48
▸ GRIA1 P42261 1/20 0.48
▸ GRIA2 P42262 1/20 0.48
▸ GRIA3 P42263 1/20 0.48
▸ SLC1A3 P43003 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18762553 1.00 GSR (0.56) GSRARG2ARG1NOS2CYP1A2
SCHEMBL188383 1.00 GSR (0.56) GSRARG2ARG1NOS2CYP1A2
Hydrochloric Acid SCHEMBL15665490 0.98 GSR (0.54) GSRARG2ARG1NOS2CYP1A2
Hydrochloric Acid SCHEMBL15665491 0.98 GSR (0.54) GSRARG2ARG1NOS2CYP1A2
SCHEMBL18791051 0.96 GSR (0.57) GSRARG2ARG1NOS2CYP1A2
SCHEMBL18774897 0.96 GSR (0.57) GSRARG2ARG1NOS2CYP1A2
SCHEMBL18774896 0.96 GSR (0.57) GSRARG2ARG1NOS2CYP1A2
Hydrochloric Acid SCHEMBL18762490 0.94 GSR (0.55) GSRARG2ARG1NOS2CYP1A2
Hydrochloric Acid SCHEMBL18762489 0.94 GSR (0.55) GSRARG2ARG1NOS2CYP1A2
Trifluoroacetic Acid SCHEMBL15670871 0.94 GSR (0.50) GSRARG2ARG1NOS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030194378-A1 Novel aerosol formulation containing a polar fluorinated molecule ASTRAZENECA AB (SE) 2003-10-16 — — US claimed
EP-1303258-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE AstraZeneca AB (SE) 2003-04-23 — — EP claimed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 — — WO claimed
EP-4687443-A1 METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE Genepep (FR) 2026-02-11 — — EP disclosed
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARM INC (US) 2026-02-05 — — US disclosed
EP-4661892-A1 TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME Navigen, Inc. (US) 2025-12-17 — — EP disclosed
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-08-05 — — US disclosed
EP-3615019-B1 MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION NAVITOR PHARM INC (US) 2025-06-04 — — EP disclosed
EP-4556069-A2 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2025-05-21 — — EP disclosed
WO-2025046244-A1 TLR3 BINDING BICYCLIC PEPTIDE LIGANDS BICYCLETX LIMITED (GB) 2025-03-06 — — WO disclosed
EP-1863832-A1 AGE INHIBITORS Pharmamens (FR) 2007-12-12 — — EP disclosed
WO-2006103274-A9 AGE INHIBITORS PHARMAMENS (FR) 2007-01-18 — — WO disclosed
EP-1303258-B1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2006-10-11 — — EP disclosed
WO-2006103274-A1 AGE INHIBITORS PHARMAMENS (FR) 2006-10-05 — — WO disclosed
WO-2004020402-A1 SULPHONYLAMINO DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE DE NOVO PHARMACEUTICALS LIMITED (GB) 2004-03-11 — — WO disclosed
CN-1455663-A Novel aerosol formulation containing polar fluorinated molecule ASTRAZENECA AB (SE) 2003-11-12 — — CN disclosed
US-20030194378-A1 Novel aerosol formulation containing a polar fluorinated molecule ASTRAZENECA AB (SE) 2003-10-16 — — US disclosed
EP-1303258-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE AstraZeneca AB (SE) 2003-04-23 — — EP disclosed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF RICTOR, RPTOR, MTOR GSR 2476/4885ARG2 290/4885ARG1 1136/4885
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 GSR 855/4885ARG2 2715/4885ARG1 4228/4885
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 GSR 855/4885ARG2 2715/4885ARG1 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.